REGENXBIO Inc. (NASDAQ: RGNX) was given a new $24.00 price target on by analysts at Leerink Partners.
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner [Yahoo! Finance]
REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $36.00 to $34.00. They now have a "buy" rating on the stock.